{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:49:37Z","timestamp":1792799377501,"version":"4.5.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0009241","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000}}],"reference-count":16,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Recent circumstantial evidence suggests increasing number of Iranian patients with cutaneous leishmaniasis (CL) who are unresponsive to meglumine antimoniate (MA), the first line of treatment in Iran. Oral meltifosine was previously reported to be effective in visceral leishmaniasis as well CL. The current study is designed to determine efficacy and safety of oral miltefosine for the treatment of anthroponotic cutaneous leishmaniasis (ACL) cases who were refractory to MA in Iran.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methodology\/Principal findings<\/jats:title>\n<jats:p>Miltefosine was orally administered for 27 patients with MA resistant ACL with approved L.tropica infection, at a dosage of \u223c2.5 mg\/kg daily for 28 days. Patients were evaluated on day 14 and 28, as well as 3, 6 and 12 month post treatment follow up sessions. Laboratory data were performed and repeated at each visit. Data were analyzed using SPSS version 17. Twenty-seven patients including 16 men (59.25%) and 11 women (40.74%) with mean age of 28.56 \u00b1 4.8 (range 3\u201354 years old) were enrolled. Total number of lesions were 42 (1\u20134 in each patient). Most of lesions were on face (76.19%). Mean lesions\u2019 induration size was 2.38 \u00b1 0.73 cm at the base-line which significantly decreased to1.31 \u00b1 0.58 cm and 0.61 \u00b10.49 cm after 14 and 28 days of therapy, respectively (p value &lt;0.05). At 12-months follow-up post treatment, 22 patients had definite\/partial cure (81.48%) including 17 definitely cured patients, corresponding to a cure rate of 68% on per protocol analysis, and 62.96% according to intention to treat analysis. Recurrence of lesion was only occurred in one patient (3.70%). Nausea was the most subjective complication during the therapy (33.33%).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Oral miltefosine could be an effective alternative for the treatment of MA-resistant ACL.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pntd.0009241","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T17:37:31Z","timestamp":1616175451000},"page":"e0009241","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7012-7205","authenticated-orcid":true,"given":"Masoumeh","family":"Tayyebi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emadodin","family":"Darchini-Maragheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouran","family":"Layegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Kiafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6615-3144","authenticated-orcid":true,"given":"Vahid Mashayekhi","family":"Goyonlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"pntd.0009241.ref001","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"J Alvar","year":"2012","journal-title":"PLoS One"},{"key":"pntd.0009241.ref002","doi-asserted-by":"crossref","first-page":"736","DOI":"10.26719\/2015.21.10.736","article-title":"Epi-demiological status of leishmaniasis in the Islamic Republic of Iran, 1983\u20132012","volume":"21","author":"MR Shirzadi","year":"2015","journal-title":"East Mediterr Health J"},{"issue":"6","key":"pntd.0009241.ref003","first-page":"9591","article-title":"Evaluation of Quality of Life, Anxiety and Depression in Children with Cutaneous Leishmaniasis","volume":"7","author":"F. Shiva","year":"2019","journal-title":"International Journal of Pediatrics"},{"issue":"3","key":"pntd.0009241.ref004","doi-asserted-by":"crossref","first-page":"e0004495","DOI":"10.1371\/journal.pntd.0004495","article-title":"Treatment of Cutaneous Leishmaniasis Caused by Leishmania aethiopica: A Systematic Review","volume":"10","author":"J van Griensven","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"pntd.0009241.ref005","doi-asserted-by":"crossref","first-page":"e1436","DOI":"10.1371\/journal.pntd.0001436","article-title":"Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine","volume":"5","author":"TPC Dorlo","year":"2011","journal-title":"PLOS Neglected Tropical Diseases"},{"key":"pntd.0009241.ref006","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(98)04367-0","article-title":"Trial of oral miltefosine for visceral leishmaniasis","volume":"352","author":"S Sundar","year":"1998","journal-title":"Lancet"},{"key":"pntd.0009241.ref007","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1086\/380638","article-title":"Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India","volume":"38","author":"SK Bhattacharya","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pntd.0009241.ref008","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.actatropica.2007.05.005","article-title":"Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran","volume":"103","author":"M Mohebali","year":"2007","journal-title":"Acta Trop"},{"issue":"5","key":"pntd.0009241.ref009","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1371\/journal.pmed.0030162","article-title":"Unresponsiveness to Glucantime Treatment in Iranian Cutaneous Leishmaniasis due to Drug-Resistant Leishmania tropica Parasites","volume":"3","author":"R Hadighi","year":"2006","journal-title":"PLOS Medicine"},{"key":"pntd.0009241.ref010","doi-asserted-by":"crossref","first-page":"E57","DOI":"10.1086\/322689","article-title":"Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent","volume":"33","author":"J Soto","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"9","key":"pntd.0009241.ref011","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/383321","article-title":"Miltefosine for New World Cutaneous Leishmaniasis","volume":"38","author":"J Soto","year":"2004","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"pntd.0009241.ref012","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1371\/journal.pntd.0000912","article-title":"Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil: A Randomized and Controlled Trial","volume":"4","author":"PR Machado","year":"2010","journal-title":"PLOS Neglected Tropical Diseases"},{"key":"pntd.0009241.ref013","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.actatropica.2011.02.007","article-title":"Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World","volume":"118","author":"LF Oliveira","year":"2011","journal-title":"Acta Trop"},{"key":"pntd.0009241.ref014","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"TP Dorlo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"pntd.0009241.ref015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/14787210.4.2.177","article-title":"Miltefosine: oral treatment of leishmaniasis","volume":"4","author":"J. Soto","year":"2006","journal-title":"Expert Rev. Anti Infect. Ther"},{"issue":"8","key":"pntd.0009241.ref016","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1517\/14656566.6.8.1381","article-title":"Miltefosine to treatment leishmaniasis: drug evaluation","volume":"6","author":"J. Berman","year":"2005","journal-title":"Expert Opin. Pharmacother"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0009241","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T17:37:43Z","timestamp":1617989863000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009241"}},"subtitle":[],"editor":[{"given":"Christine A.","family":"Petersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0009241","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0009241","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]}}}